Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2012-12-12 19:21:37
Reporting Period:
Filing Date:
Accepted Time:
2012-12-12 19:21:37
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1369568 Catalyst Pharmaceutical Partners Inc. CPRX Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1048477 Biomarin Pharmaceutical Inc 105 Digital Drive
Novato CA 94949
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-12-08 5,000,000 $0.75 6,666,667 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Convertible Promissory Note and Note Purchase Agreement Disposition 2012-12-08 5,000,000 $0.00 6,666,667 $0.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2012-12-08 2012-12-08 No 4 J Direct
  1. BioMarin Pharmaceuticals, Inc. held a Convertible Promissory Note and Purchase Agreement ("Convertible Note") in the aggregate amount of $5,000,000 that automatically converted into 6,666,666 shares of Common Stock of Catalyst Pharmaceuticals, Inc. at a conversion price of $0.75 per share on December 8, 2012. The number of shares issuable upon conversion of the Convertible Note was determined by dividing the aggregate principal amount of the note, $5,000,000 by the "Conversion Price" in effect on December 8, 2012. The Conversion Price was the dollar weighted average price of the Common Stock for the 15 business day period prior to December 8, 2012, multiplied by 0.9; provided, however, that the Conversion price could not be less than $0.75 per share or more than $2.50 per share.